7,733 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Acquired by Generali Asset Management SPA SGR

Generali Asset Management SPA SGR purchased a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 7,733 shares of the specialty pharmaceutical company’s stock, valued at approximately $952,000.

Several other hedge funds have also recently bought and sold shares of JAZZ. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Jazz Pharmaceuticals by 135.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after purchasing an additional 100,112 shares during the last quarter. Centre Asset Management LLC acquired a new position in Jazz Pharmaceuticals in the fourth quarter valued at about $9,335,000. Moloney Securities Asset Management LLC acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth approximately $464,000. Pacer Advisors Inc. increased its holdings in shares of Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after buying an additional 278,465 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in Jazz Pharmaceuticals by 4.6% during the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock worth $124,208,000 after acquiring an additional 48,708 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

JAZZ has been the subject of several research analyst reports. Royal Bank of Canada cut their price objective on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. Truist Financial lifted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their price target for the stock from $140.00 to $150.00 in a research report on Wednesday, February 26th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the company from $145.00 to $179.00 in a research report on Friday, March 7th. Finally, Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th. One research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $187.71.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,140 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $137.81, for a total transaction of $157,103.40. Following the transaction, the chief accounting officer now owns 7,012 shares in the company, valued at approximately $966,323.72. This trade represents a 13.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the transaction, the chief executive officer now owns 439,744 shares of the company’s stock, valued at $53,785,088.64. The trade was a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock worth $4,022,825 in the last three months. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $140.57 on Friday. The company has a fifty day moving average price of $131.07 and a two-hundred day moving average price of $121.46. The firm has a market capitalization of $8.54 billion, a PE ratio of 19.80, a P/E/G ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.